GGGuanghui Gao

Guanghui Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guanghui Gao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Fengying Wu

    Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, P. R. China

    3 shared publications
  • Lingyun Ye

    Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China

    3 shared publications
  • Tao Jiang

    Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China

    3 shared publications
  • Caicun Zhou

    Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

    2 shared publications
  • Chunxia Su

    Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China

    2 shared publications
  • Fei Zhou

    Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    A cilia-associated signature predicts resistance to anti-PD-1 immune checkpoint blockade therapy in lung adenocarcinoma

    by Fei Zhou, Gaohua Feng, Xiaoshen Zhang, Changbin Zhu, Tao Jiang, Tao Hu, Wei Li, Jun Ni, Qian Li, Zhan Huang, et al.

    Targeting immune checkpoints, specifically programmed death 1, has significantly improved clinical outcomes in non-small cell lung cancer. However, only a proportion of patients benefited from immune checkpoint blockades (ICBs) therapy. Thus, identifying novel biomarkers to better select responders to ICBs is critically important in clinical practice. This retrospective study included two cohorts, a discovery cohort (n = 24) and a validation cohort (n = 21) of lung adenocarcinoma (LUAD) patients treated with ICB at Shanghai Pulmonary Hospital between April 2016 and November 2019. Formalin-fixed paraffin-embedded tissue samples were collected for RNA sequencing. Additionally, a TCGA dataset (GSE135222) and a clinical study dataset (POPLAR) were utilized as external validation and test sets, respectively. In the discovery cohort, cilia-associated pathways were significantly enriched in LUAD patients with non-durable benefit. A three-gene cilia-associated signature (TMEM100, DNAH3, and NEFH) was established and effectively predicted resistance to ICB treatment (discovery cohort, Hazard Ratio [HR, 95% CI] = 0.21 [0.056-0.791], P = 3.64e-05; validation cohort, HR [95% CI] = 0.200 [0.049-0.830], P = 0.0003). This signature was further validated in an external cohort (HR [95% CI] = 0.461 [ 0.164-1.292], P = 0.067). Further analysis demonstrated that the cilia-associated signature was negatively associated with various types of tumor-infiltrating immune cells, including effector T cells, macrophages, and dendritic cells. Our findings suggest that cilia-associated signature may serve as a potential biomarker to identify LUAD patients with reduced likelihood of benefiting from ICB therapy, though further validation in larger cohorts is warranted.

  • Open Access

    Exploration of patient plasma exosomes as biomarkers for predicting lung cancer brain metastasis

    by Lingyun Ye, Xinnan Hu, Shen Chen, Hai Wang, Juanjuan Li, Lei Wang, Guanghui Gao, Xiaoxia Chen, Xiao Song

    Background: Many studies have found that exosomes have numerous advantages in the early diagnosis of tumors. We detected and analyzed plasma exosomes from lung cancer patients to identify potential biomarkers that could predict brain metastasis. Method: The total RNA of plasma exosomes of advanced lung cancer patients was extracted and sequenced. The BLAST software was used to align the predicted target gene sequence against the GO and KEGG databases, thereby acquiring annotation details for the target genes. The selected exosomal miRNAs and short-chain fatty acids were subjected to diagnostic performance validation analysis. Results: Exosomal miR-223-3p, miR-27a-3p, and miR-27b-3p were significantly increased in the plasma exosomes of lung cancer patients with brain metastasis. The concentrations of isobutyric acid (IBA), valeric acid (VA), isovaleric acid (IVA), and acetic acid (AA) were markedly elevated in the plasma exosomes of lung cancer patients with brain metastasis. Spearman correlation analysis revealed that both miR-27a-3p and miR-27b-3p had significant associations with IVA and VA. A multi-biomarker model combining the selected exosomal miRNAs with metabolic molecules could improve the diagnostic performance with an AUC of 0.927. Conclusion: Plasma exosomal miR-223-3p, miR-27a-3p, miR-27b-3p, and IBA, IVA, VA, and AA in advanced patients are closely associated with brain metastasis and have the potential to act as biomarkers for predicting brain metastasis in lung cancer patients.


  • Open Access

    WISP3 upregulates SDCBP expression to promote the progression of non-small cell lung cancer via the TGF-β signaling pathway

    by Xiaoshen Zhang, Tao Jiang, Lingyun Ye, Jianguo Sun, Lei Wang, Juanjuan Li, Fengying Wu, Shengxiang Ren, Guanghui Gao


  • Open Access

    Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway

    by Fei Zhou, Jianguo Sun, Lingyun Ye, Tao Jiang, Wei Li, Chunxia Su, Shengxiang Ren, Fengying Wu, Caicun Zhou, Guanghui Gao

    Background: Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple cancer types. However, the roles and the underlying mechanism of fibronectin on the progression NSCLC need to be further elucidated. Methods: Public dataset such as Kaplan-Meier Plotter was used to determine the prognostic significance of genes. The correlation of different protein expression in clinical and xenograft tissues was tested by immunohistochemistry experiment. Both in vitro and in vivo experiments were performed to determine the role of fibronectin on the tumor growth, metastasis, and angiogenesis in NSCLC. The activation of key signaling pathway under fibronectin was examined by WB assay. RNA-seq was applicated to screening the target gene of fibronectin. Rescue experiment was performed to confirm the role of target gene in fibronectin-mediated function in NSCLC. Finally, luciferase and CHIP assays were used to elucidate the mechanism by which fibronectin regulated the target gene. Results: Our results revealed that fibronectin was up-regulated in cancer tissues compared with the normal ones in NSCLC patients. Dish- coated fibronectin enhanced the tumor growth, metastasis, and angiogenesis of NSCLC in vitro and in vivo by promoting EMT and maintaining stemness of NSCLC cells. As expected, fibronectin activated FAK and its downstream MAPK/ERK signaling pathway. WISP3 was screened as a potential target gene of fibronectin. Interestingly, WISP3 effectively activated Wnt signaling pathway, and knockdown of WISP3 effectively blocked the influence of fibronectin on the migration, invasion and vascular structure formation potential of NSCLC cells. Our data also manifested that fibronectin elevated the transcription of WISP3 gene by promoting the binding of HIF-1α to the promoter region of WISP3 in NSCLC cells. Conclusions: Our findings sketched the outline of the route for fibronectin exert its role in NSCLC, in which fibronectin activated downstream FAK and MAPK/ERK signaling pathways, and mediated the accumulation of HIF-1α. Then, HIF-1α enabled the transcription of WISP3, and subsequently promoted the activation of Wnt signaling pathway, and finally enhanced the tumor growth, metastasis, and angiogenesis in NSCLC.